THE HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ABACAVIR AND LAMIVUDINE IN FIRST-LINE ANTIRETROVIRAL THERAPY REGIMENS
- Autores: KRAVCHENKO A.V1, KANESTRI V.G1
-
Afiliações:
- Federal Scientific-and-Methodic Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow
- Edição: Nº 2 (2011)
- Páginas: 49
- Seção: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/287267
- ID: 287267
Citar
Texto integral
Resumo
The review gives the results of a few large trials (CNA 30024, HEAT, STEAL, BICOMBO, ACTG 5202, ACTG 5224s, SWIFT, ASSERT) of the efficacy and safety of antiretroviral therapy (ARVT) regimens incorporating the HIV nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. W hen ARVT regimens are used today, the fixed-dose combinations of NRTIs (Combivir ® , Kivexa ® , Truvada ® ) have certain benefits of reducing the number of drugs and the frequency of their administration. Since Kivexa and Truvada have a comparable virological efficacy and a good tolerability, they are included into first-line ARVT regimens as recommended in most current guidelines. When a patient is given an abacavircontaining ARVT regimen, he/she should have genetic testing for the HLA-B*5701 allele in order to minimize a risk for developing a hypersensitivity reaction (near 100% negative predictive value). On choosing the optimal first-line ARVT regimen for a specific patient, the physician should consider the whole spectrum of possible adverse reactions, comorbidity, drug interactions, and the living conditions of a HIV-infected patient.
Texto integral
Sobre autores
A. KRAVCHENKO
Federal Scientific-and-Methodic Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow
Email: kravtchenko@hivrussia.net
V. KANESTRI
Federal Scientific-and-Methodic Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow
Bibliografia
- Бартлетт Д., Галлант Д., Фамп П. Клинические аспекты ВИЧ-инфекции 2009-2010. М.: Р. Валент; 2010.
- ВИЧ-инфекция и СПИД: Клинич. рекомендации. /Под ред. В.В. Покровского. М.: ГЭОТАР-Медиа; 2010.
- Clinical management and treatment of HIV-infected adults in Europe, EACS Guidelines, Version 5-4, March, 2011 (http: www.europeanaidsclinicalsociety.org).
- Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. Developed by the panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services (DHHS). 10 January 2011. Available from http: www.AIDSinfo.nih. gov.
- Thompson M.A., Aberg J.A., Cahn P. et al. Antiretroviral Treatment of Adult HIV Infection 2010 Recommendations of the International AIDS Society USA Panel. J.A.M.A. 2010; 304: 321-333.
- WHO: Antiretroviral therapy for HIV infection in adults and adolescents, Guidenlines, March 2010 (http://www.who. int/topics/hiv_aids/en/ index.html).
- De Jesus E., Herrera G., Teofilo E. et al. The CNA30024 study team abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 2004; 39: 1038-1046.
- Shafer M.S., Smith K.Y., Patel P. et al. (for the HEAT Study Team). Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23(12): 1547-1556.
- Stellbrink H.J., Moyle G., Orkin C. et al. Assessment of Safety and Efficacy of Abacavir/Lamivudine and tenofovir/ Emtricitabine in Treatment-Naive HIV-1 Infected Subjects. ASSERT: 48-Week Result. 12th European AIDS Conference. Cologne, Germany. 11-14 November 2009. PS10/1.
- Daar E., Tierney C., Fischl M. et al. ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients. Program and abstracts of the 17th Conference on retroviruses and Oopportunistic infections. San Francisco, California. 16-19 February 2010. Abstract 59LB.
- Martınez E., Arranz J.A., Podzamczer D. et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression (BICOMBO). J. Acquir. Immune Defic. Syndr. 2009; 51(3): 290-297.
- Martin A., Bloch M., Amin J. et al. Simplification of antiretroviral therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: a randomized, 96-week trial (STEAL). Clin.Infect. Dis. 2009; 49: 1591-1601.
- Campo R., DeJesus E., Khanlou H. et al. SWIFT study: switching from lamivudine/abacavir (3TC/ABC) to emtricitabine/tenofovir DF (FTC/TDF) maintained efficacy and reduced virologic failure. 6th International AIDS Society (IAS) Conference on HIV Рathogenesis, Treatment and Prevention. Rome, Italy. 17-20 July 2011. Abstract WELBB03.
- Ha B., Liao Q.M., Dix L.P., Pappa K.A. Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies. HIV Clin. Trials. 2009; 10(2): 65-75.
- Туманов А.С., Лага В.Ю., Казеннова Е.В. и др. Оценка распространенности аллеля HLA-B*5701 среди ВИЧ-инфицированных лиц на территории европейской части Российской Федерации. Мед. генетика 2010; 8: 36-39.
- Palella F. J., Gange J., Stephen J. et al. Inflammatory biomarkers and abacavir use in the Women’s Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24(11): 1657-1665.
- Ding X., Andraca-Carrera E., Cooper C. et al. No association of miocardial infarction with abacavir use: Findings of an FDA meta-analisis. Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston MA, USA. 2011. Abstract 808.
- McComsey G., Kitch D., Daar E. et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, California. 16-19 February 2010. Abstract 106LB.
Arquivos suplementares
